

2 **Virtual reality and mobile phones in the treatment of generalized**
3 **anxiety disorders: a phase-2 clinical trial**

4 **Claudia Repetto · Andrea Gaggioli ·**
5 **Federica Pallavicini · Pietro Cipresso ·**
6 **Simona Raspelli · Giuseppe Riva**

7 Received: 22 January 2011 / Accepted: 20 June 2011
8 © Springer-Verlag London Limited 2011

9 **Abstract** Several studies have demonstrated that expo-
10 sure therapy—in which the patient is exposed to specific
11 feared situations or objects that trigger anxiety—is an
12 effective way to treat anxiety disorders. However, to
13 overcome a number of limitations inherent in this
14 approach—lack of full control of the situation, costs and
15 time required, etc.—some therapists have started to add
16 virtual reality (VR) to the in vivo exposure-based therapy,
17 providing in-office, controlled exposure therapy. Compared
18 to the in vivo exposure, VR Exposure Therapy (VRET) is
19 completely controlled: the quality, the intensity and the
20 frequency of the exposure are decided by the therapist, and
21 the therapy can be stopped at any time if the patient does
22 not tolerate it. Moreover, the flexibility of a virtual expe-
23 rience allows the patient to experience situations that are
24 often much worse and more exaggerated than those that are
25 likely to be encountered in real life. However, a critical
26 issue underlying the use of VRET in the treatment of
27 anxiety-related disorders is the lack of a virtual reality
28 system in the patient's real-life context. In this paper, we
29 present a clinical protocol for the treatment of Generalized

Anxiety Disorders (GAD) based on the ubiquitous use of a 30
biofeedback-enhanced VR system. The protocol includes 31
the use of a mobile exposure system allowing patients to 32
perform the virtual experience in an outpatient setting. A 33
between-subjects study, involving 25 GAD patients, was 34
carried out to verify the efficacy of the proposed approach. 35
The clinical data in this pilot study seemed to support the 36
efficacy of the ubiquitous approach. 37
38

Keywords Virtual reality · Mobile phones · Generalized 39
anxiety disorders · Clinical trial · Ubiquitous computing 40

39 **1 Introduction** 41

Anxiety is a typical human emotion that people experience 42
when some crucial personal goals (i.e. safety, self esteem, 43
approval, etc.) are challenged and the subject forecasts an 44
oncoming bust [1]. In most cases, anxiety can be consid- 45
ered as a normal reaction to a demanding emotional con- 46
text: in such cases, people are able to deal with this 47
emotional activation spontaneously by applying strategies 48
that allow a cognitive resizing of the source of worry and a 49
consequent positive management of the situation. 50

However, a level of anxiety which is so high as to 51
prevent people from leading a normal life constitutes an 52
anxiety disorder. Anxiety disorders are very common 53
worldwide [2, 3] and have a considerable impact on per- 54
sonal and professional life: usual activities become very 55
stressful and this leads people to avoid the feared situation 56
or to undertake rumination activities. Avoidance behav- 57
iours tend to worsen with time and start a vicious circle: in 58
terms of conditioning paradigms, avoidance behaviours are 59
negative reinforcements since they prevent an aversive 60
symptom (anxiety); however, they also maintain the link 61

A1 C. Repetto (✉) · G. Riva
A2 Department of Psychology, Università Cattolica del Sacro
A3 Cuore, Largo Gemelli 1, 20123 Milan, Italy
A4 e-mail: claudia.repetto@unicatt.it

A5 A. Gaggioli · F. Pallavicini · P. Cipresso · S. Raspelli · G. Riva
A6 Applied Technology for Neuro-Psychology Lab,
A7 Istituto Auxologico Italiano, Milan, Italy

A8 A. Gaggioli
A9 ICE-NET Lab, Università Cattolica del Sacro Cuore, Milan, Italy

A10 F. Pallavicini · S. Raspelli
A11 Centre for Studies in Communication Sciences,
A12 University of Milan-Bicocca, Milan, Italy

62 between conditioned and unconditioned stimuli, preventing
63 the extinction phenomenon. Furthermore, rumination trig-
64 gers a vicious circle in which the source of worry is
65 increasingly present in the subjects' mind and becomes an
66 intrusive and persecutory thought. People suffering from
67 anxiety disorders usually do not recover spontaneously and
68 have to undergo a specific treatment. Many different
69 treatments are now available for anxiety disorders:
70 behavioural treatments, cognitive psychotherapy, medica-
71 tion and biofeedback are among the most used. Several
72 studies investigating the effectiveness of the various
73 treatments have demonstrated that exposure-based thera-
74 pies are more suitable and effective than others [4–12].

75 The exposure process involves the patient's progressive
76 exposure to the situation that causes anxiety. Exposure
77 alone, without relaxation training, has proved effective to
78 treat a number of anxiety disorders and phobias, such as
79 panic disorders, agoraphobia [6], social phobia [13] and
80 obsessive–compulsive disorders [9]. However, in the case
81 of systematic desensitization [14], exposure is used in
82 combination with relaxation, an emotional and physiolog-
83 ical state considered incompatible with anxiety [15]. In
84 these protocols, the patient learns how to manage the
85 symptoms of anxiety by replacing emotional maladaptive
86 activation with relaxation. Since patients have the oppor-
87 tunity to monitor their thoughts and beliefs with the ther-
88 apist while experiencing anxiety, they can reduce their
89 cognitive attributions. Exposure may be achieved by dif-
90 ferent means: in vivo, through direct contact with the
91 stimulus, by imagery, and more recently using virtual
92 reality (VRET). However, despite their effectiveness, the
93 first two types of exposure present some limitations: some
94 patients report difficulties to imagine the feared situation
95 because of poor abilities in creating mental images and in
96 getting inside a specific situation. In vivo exposure poses
97 other critical issues: first of all, many patients are rather
98 unwilling to expose themselves to the real situation since it
99 is considered too frightening; second, the therapist is not
100 fully in control of the real situation; third, the costs and
101 time requirements are considerable since the therapist and
102 the patient usually meet each other outside the therapist's
103 office to work together on the stimulus target. For all these
104 reasons, VRET has take root in the treatment of anxiety
105 disorders in the last few decades.

106 As a matter of fact, VRET presents several advantages
107 when compared with the traditional treatments using both in
108 vivo and imagination techniques. First of all, the stimulus is
109 under the full control of the therapist, who has the opportu-
110 nity to select an emotional intensity suitable to each patient
111 as well as the hierarchical order of the stimuli that trigger
112 anxiety; furthermore, during the VRET, the session can be
113 stopped in case of excessive emotional activation (which is,
114 however, extremely rare). In this way, the patient feels less

115 uncomfortable about the treatment and his/her motivation
116 increases. Compared to imagination, VRET offers the pos-
117 sibility to visualize a realistic environment and to interact
118 with it, without making any imaginative effort.

119 Another field of application that could take advantage
120 from the above mentioned use of virtual reality for the
121 treatment of anxiety disorders is the Stress Inoculation
122 Training (SIT) [16]. SIT has been employed to prevent the
123 disorder and to treat individuals who have experienced
124 stress responses. The purpose of the treatment is to help
125 patients to cope with various form of stress and sources of
126 worry [16–18]. After this kind of intervention, patients
127 should be able to bolster their coping repertoire (intra- and
128 interpersonal skills) and should become more confident in
129 their own abilities to apply coping strategies in a flexible
130 way depending on the context.

131 Furthermore, VR lends itself to be associated with bio-
132 feedback training, especially if aimed at relaxation. Bio-
133 feedback is a coaching and training technique that helps
134 people learn how to change physiological response pat-
135 terns, in order to improve their mental and emotional
136 functioning. Being connected to psychophysiological bio-
137 sensors, the person uses the information provided as
138 feedback to increase awareness or consciousness of the
139 changes in the body/mind function. The feedback could be
140 delivered by visual or acoustic signals. Virtual environ-
141 ments are known to facilitate relaxation, reducing stress
142 and improving positive emotional states [19, 20]; more-
143 over, the sense of presence and the immersive visual cue
144 make the virtual environments a privileged place where
145 visual and highly significant feedback could be provided.

146 1.1 The mobile dimension as a tool for ubiquitous 147 treatment

148 It should be noticed that a critical issue related to the use of
149 virtual exposure in the treatment of anxiety disorders is the
150 lack of availability of VR systems in the patient's real-life
151 context: both the cost and the setting of the system limit its
152 use to the health care centre/hospital/therapist's office. The
153 possibility to do the exercises trained with the therapist in
154 the real life has at least two functions: first of all, cognitive-
155 behavioural exercises are very powerful techniques but
156 need to be learned and repeated over time in order to be
157 correctly applied and to be effective. In this perspective,
158 the availability of VR outside the therapist's office is
159 critical to speed up the learning process and achieve
160 quickly clinical results. Second, the patient experiences the
161 emotions of anxiety and fear spontaneously in everyday
162 life due to the natural exposure to events that cause such
163 emotional activations; for this reason, the support of VR as
164 a portable device is required to deal with the stressful sit-
165 uations (i.e. doing a relaxation exercise).

166 A promising tool that, from a technological point of
 167 view, already meets the requirements needed to support VR
 168 environments and, at the same time, is portable and easily
 169 available is the mobile phone. The role of mobile phones as
 170 a tool for responding to a variety of clinical needs has been
 171 recently investigated [21]. The interest for this device is
 172 motivated by its wide diffusion: the penetration of mobile
 173 phones in the world population has rapidly increased in the
 174 last few decades, also thanks to its decreasing price. Fur-
 175 thermore, the advanced technology now available makes
 176 mobile phones something more than a calling device: new
 177 generation mobile phones are able to achieve broader
 178 communication capabilities, supporting 3D graphics, pic-
 179 tures, sounds and software. Preziosa et al. (ibidem) dis-
 180 cussed the results of two studies based on the use of mobile
 181 phones for anxiety management. In the first experiment, a
 182 Stress Inoculation Training was used to reduce examina-
 183 tion stress: The data supported the hypothesis that the
 184 combination of video and audio narratives administered via
 185 UMTS induced more relaxation when compared with the
 186 other experimental conditions (either video or narratives
 187 administered with alternative means, such as CD and MP3
 188 players). In the second study, mobile phones were used to
 189 train the ability to relax in a group of stressed patients by
 190 administering mobile narratives. The outcome of this
 191 research, together with other experimental studies on
 192 mobile phones, suggests that this technology is promising
 193 in the treatment of anxiety disorders, since it offers the
 194 opportunity to bridge the gap between inpatient and out-
 195 patient sessions.

196 In this paper, we present a clinical protocol for the
 197 treatment of Generalized Anxiety Disorders (GAD) based
 198 on the ubiquitous use of a biofeedback-enhanced virtual
 199 reality (VR) system. The paper also describes the results of
 200 a phase-2 controlled trial (NCT00602212) involving 24
 201 GAD patients.

202 1.2 The treatment of generalized anxiety disorders:
 203 a ubiquitous approach

204 Generalized Anxiety Disorder (GAD) is a psychiatric dis-
 205 ease characterized by long-lasting anxiety that is not
 206 focused on a specific object or situation. According to the
 207 DSM-IV-TR (APA, 2000), the essential feature of GAD is
 208 at least 6 months of “excessive anxiety and worry” about a
 209 variety of events and situations. Anxiety and worry are
 210 often accompanied by a variety of physical symptoms like
 211 restlessness, being easily fatigued, difficulty in concen-
 212 trating, irritability, muscle tension and disturbed sleep. The
 213 high prevalence of GAD in the general population and the
 214 severe limitations it causes point out the necessity to find
 215 new strategies to treat it in a more efficient way. Within the
 216 treatment of GAD, physical (relaxation and controlled

breathing), behavioural (visualization and controlled
 exposure) and cognitive control strategies (challenging
 negative thoughts) represent a key part of the treatment,
 even if they are hard to learn. Given the features of this
 disease and its pervasive effect on patients’ personal,
 professional and affective life, we thought it could benefit
 from a ubiquitous treatment. Therefore, we suggested to
 improve the treatment of GAD through the use of a bio-
 feedback-enhanced virtual reality (VR) system used for
 relaxation, controlled exposure [22, 23] and SIT. The use
 of SIT in the context of GAD is motivated by the
 acknowledgment that sometimes stressors cannot be avoi-
 ded or altered [24] and then patients cannot apply strategies
 focused on finding solutions. In these cases, the coping
 effort should be directed to an emotionally palliative set of
 responses such as acceptance, reframing and perspective
 thinking. All these cognitive changes are facilitated if
 relaxation is induced at the same time. The treatment
 involves two virtual reality components (see Fig. 1): (1) an
 immersive virtual reality system experienced in the thera-
 pist’s office; (2) a mobile exposure system allowing
 patients to perform the virtual experience in an outpatient
 setting. The role of the mobile exposure system is the
 following:

- To present and structure emotionally relevant contents in a ubiquitous context.
- To verify the patient’s compliance and, if necessary, alert the patient/therapist;
- To track the emotional level of the patient in real time and record it for later assessment by the therapist;
- To provide feedback to the patients to help them cope with the contents;




Fig. 1 Consort flowchart for randomized trial

249	• To contact the therapist automatically if the emotional level is higher than a preset cut-off value defined by the therapist.	296
250		
251		
252	The critical features of the mobile system in a real clinical context are:	
253		
254	• <i>Cost effectiveness</i> : even with the creation of PC-based VR, the cost of a VR system is still too expensive for the typical patient (2,000/3,000 € for a non-immersive system). Our goal was to develop a system with a price <1,000 €.	297
255		
256		
257		
258		
259	• <i>Usability</i> : the mobile system has to be simple enough to be used by an unsupervised patient after some training sessions.	298
260		
261		
262	• <i>Use of easily available technology</i> : the mobile system has to be based as much as possible on off-the-shelf components and protocols.	299
263		
264		
265	• <i>Emotional response</i> : the mobile system has to be emotionally connected with the contents of the VR sessions experienced in the health care centre/hospital/therapist’s office. This can be achieved by presenting on the mobile system a non-navigable version of the same virtual reality environment experienced during the therapy. Some features of the experience—speed, contents, etc.—were driven by the emotional status of the patient.	300
266		
267		
268		
269		
270		
271		
272		
273		
274	For these reasons, the technology used in the protocol is the following:	301
275		
276	• A wireless (Bluetooth) multi-sensor module (GSR/HR Sensor Module including finger sensors that simultaneously measure heart rate and electrodermal activity, GSR).	302
277		
278		
279		
280	• The Virtual Reality control unit: Asus G2S portable computer with Intel® Core™2 Extreme Processor X7800, Nvidia GeForce 8600 GT 256 MB DDR3 graphic card, Bluetooth support.	303
281		
282		
283		
284	• A head-mounted display: Vuzix iWear VR920 with twin high-resolution 640 × 480 (920,000 pixels) LCD displays, iWear® 3D compliant.	304
285		
286		
287	• The therapist’s netbook, (EEPC 100H-BK039X) used to control in real time the features of the virtual environment and to assess physiological parameters.	305
288		
289		
290	• A joypad (Xbox Controller)	306
291		
292	• A Smartphone (HTC Touch Pro T7272) for relaxation homework. The Smartphone uses the Windows Mobile® 6.1 Professional operating system. It also includes a 2.8-inch TFT-LCD flat touch-sensitive screen with VGA resolution	307
293		
294		
295		
		308
		309
		310
		311
		312
		313
		314
		315
		316
		317
		318
		319
		320
		321
		322
		323
		324
		325
		326
		327
		328
		329
		330
		331
		332
		333
		334
		335
		336
		337
		338
		339

2 Testing the approach: a phase-2 controlled trial	296
2.1 The sample	297
One hundred and sixty-six consecutive patients seeking treatment in a public health care institute in Italy were seen for screening interviews for admission to the study. Criteria for participation in the study included: (1) Diagnosis of GAD according to DSM-IV-TR criteria; (2) Age between 18 and 50 years; (3) No psychotherapy received for GAD; (4) In case of pharmacotherapy, the kind and amount of medication should not have varied during the experimental period; (5) No history of neurological diseases, mental retardation, psychosis, alcohol or drug addiction; (6) No migraine, headache or vestibular abnormalities; (7) Women who were pregnant or breastfeeding were also excluded.	298
Of these, 141 either did not fulfil the inclusion criteria or were excluded for other reasons (e.g. time constraints, involvement in other treatments, refusal to participate). All the 25 patients who met the inclusion criteria (16 women and 9 men) entered the treatment phase. The majority of them (65%) had graduated from upper secondary school, were employed at the time of the study and were married.	299
The study was approved by the Ethical Committee of the Istituto Auxologico Italiano and was recorded in the Clinicaltrials.gov database with the official trial number “NCT00602212”.	300
2.2 Assessment tools	301
A semi-structured interview was used to identify relevant DSM-IV-TR diagnostic criteria for GAD in the sample.	302
The following psychometric questionnaires were also administered to each patient at pre-treatment and upon completion of the Beck Anxiety Inventory (BAI, [25]), a 21-item scale measuring cognitive, behavioural and physiological symptoms of anxiety.	303
• State-Trait Anxiety Inventory Form Y-2 (STAI-Y [26]), a 2-scale questionnaire including 20 items each, that measures anxiety in adults. The STAI clearly differentiates between the temporary condition of “state anxiety” (STAY-Y1) and the more general and long-standing quality of “trait anxiety” (STAY-Y2).	304
• Hamilton Anxiety Rating Scale (HAM-A [27]). The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety).	305

340 2.3 Protocol

341 The patients were randomly assigned to the following
 342 groups (see Fig. 1—Consort Flow Chart—for detail): (1)
 343 the VR and Mobile group (VRMB) including a biofeed-
 344 back-assisted relaxation program—7 subjects; (2) the VR
 345 and Mobile group (VRM) without biofeedback—9 sub-
 346 jects; (3) the waiting list (WL) group—8 subjects:

- 347 1. *Virtual reality + mobile phone without biofeedback*
 348 *condition (VRM)*. In this experimental condition,
 349 patients received an eight-session VR-based treatment
 350 including both relaxation and exposure techniques. In
 351 sessions 1–6, the patients explored a beautiful VR
 352 tropical island (experienced with a head-mounted
 353 display and head-tracking) following a predefined path
 354 leading to different relaxing areas: Campfire, Beach
 355 and Waterfall. In these areas, the patients started to
 356 relax by observing the flickering campfire, watching
 357 waves lapping gently on a shore or looking to the
 358 waterfall and fish pond. Each experience was sup-
 359 ported by an audio narrative based on progressive
 360 muscle relaxation and/or autogenic techniques. All the
 361 environments were developed by the ESIEA INTRE-
 362 PID team (J. L. Dautin, J. Ardouin, F. Crison and M.
 363 Le Renard—www.esiea.fr) using the 3DVIA 4.1 Vir-
 364 tools toolkit by Dassault Systèmes—
 365 www.virtools.com. To improve the efficacy of the
 366 training and to increase the effects of relaxation,
 367 patients could access a non-navigable version of the
 368 same virtual reality environment experienced during
 369 the therapy also from home using a mobile phone. The
 370 patient was asked to train relaxation abilities at least
 371 once a day for the entire duration of the treatment
 372 according to the plan provided by the therapist. In
 373 sessions 7 and 8, the patients explored the island again
 374 and reached a gazebo in which they were exposed to
 375 pre-selected words or images related to their personal
 376 stressful events. The patients were then asked to use
 377 the relaxation techniques they had learned to cope with
 378 them.
- 379 2. *Virtual reality + mobile phone with biofeedback con-*
 380 *dition (VRMB)*. The patients followed the same
 381 protocol described above with biofeedback support
 382 (see Figs. 2, 3). During the sessions, the therapist used
 383 HR variations [28–31] to modify specific features of
 384 the virtual environment:
- 385 (a) *Campfire (sessions 1–2)*. HR controls the fire
 386 intensity: a reduction in the patient’s physiologi-
 387 cal activation reduces the intensity of the fire
 388 until it disappears;
- 389 (b) *Beach (sessions 3–4)*. HR controls the movement
 390 of the waves: a reduction in the patient’s



Fig. 2 A screenshot from the VR environment experienced by the VRM Group. The figure illustrates a campfire, one of the relaxing environments showed to the patients during the treatment



Fig. 3 A screenshot from the VR Biofeedback experienced by the VRMB Group. A bar placed on the right and showing the patients’ physiological parameters allows them to monitor their emotional state through in vivo measures during the relaxation exercise

- physiological activation reduces the movement 391
 of the waves until the ocean becomes completely 392
 calm; 393
- (c) *Waterfall (sessions 5–6)*: HR controls the move- 394
 ment of the water: a reduction in the patient’s 395
 physiological activation reduces the movement of 396
 the water until the water flow becomes com- 397
 pletely still; 398
- (d) *Gazebo (sessions 7–8)*: HR controls the size of a 399
 stressful image or video: a reduction in the 400
 patient’s physiological activation reduces the size 401
 of the stimulus until it disappears. This exercise 402
 is designed following the procedure of SIT. 403

3. *Waiting list condition (WL)*. This was a control condition, in which patients were included in a waiting list and did not receive any kind of relaxation training.

The randomization scheme was generated using the website www.randomization.com. After the randomization, a patient in the VRM group refused to participate in the study and abandoned the trial for family and work reasons.

2.4 Statistical analysis

A power calculation was made to evaluate the possibility of detecting statistically significant differences both between (independent measures) and within the groups (repeated measures). Given the low statistical power due to the relatively small number of participants, the non-normality of several distributions and the unbalanced groups, we decided to use the exact methods with Monte Carlo approximation, a series of non-parametric statistical algorithms that enable researchers to make reliable inferences when data are sparse, heavily tied or unbalanced, not normally distributed, or fail to meet any of the underlying assumptions necessary to obtain reliable results using the standard asymptotic method. The exact methods with Monte Carlo approximation used for the comparisons are the Kruskal–Wallis test with post hoc analysis [32] for independent measures, the Wilcoxon rank-sum test for repeated measures and the Chi-square for categorical variables, with $\alpha = 0.5$, two tailed.

2.5 Results

Non-parametric tests indicated that there were no significant differences in the age and years of education of the subjects (Table 1). Similarly, no significant differences were found in their clinical characteristics (Table 2).

2.5.1 Before/after session analysis

The GSR and the HR, as well as the STAI-Y1 were recorded at the beginning and at the end of each training session in the VRMB and in the VRM groups. Both groups were able to obtain a significant reduction (5/10% of the initial level) in both physiological (HR only) and self-assessed measures of anxiety (STAI-Y1) at the end of the

different sessions (Table 1). In particular, the ability of the subjects to attenuate HR responses during a behavioural challenge is very interesting because these situations are particularly relevant to real-life events. However, no significant differences were found between the groups.

2.5.2 Before/after treatment analysis

To evaluate the overall effect of the treatment, we analysed the treatment effects (pre- vs. post-treatment) on the psychometric variables within the 3 groups. The results (Table 3) showed:

- *VRMB group*: a significant decrease in the BAI ($Z = -1.826$; $p < .05$) and STAI-Y2 ($Z = -1.826$; $p < .05$) scores;
- *VRM group*: a significant decrease in the BAI ($Z = -2.383$; $p < .05$) scores
- *WL group*: no significant changes.

Non-parametric K-Independent Tests were also used to analyse the differences between the subjects in the pre- and post-treatment anxiety questionnaires. Given the limited statistical power, no significant differences were found for $p < .05$.

3 Discussion

Different VR applications for the understanding, assessment and treatment of mental health problems have been developed over the last 15 years [33, 34].

Even if VR offers several advantages when compared with traditional cognitive-behavioural procedures, the fact that VR tools are confined to the therapist's office has been recognized as a limitation, especially for the treatment of anxiety disorders. This experiment evaluated the possibility to use a ubiquitous approach, based on a virtual environment uploaded on a mobile phone, for the treatment of GAD. Even if the small sample leads us to consider the study as a pilot one, it achieved two interesting results. On the one hand, it confirmed the possibility of using VR in the treatment of GAD. Both experimental groups had better clinical outcomes at the end of the treatment. On the other hand, it supported the clinical use of a mobile phone to re-

Table 1 Anxiety differences in pre- and post-sessions

	Group	Mean	SD
Mean of HR differences (pre–post, all sessions)	VRMB	5.71	2.34
	VRM	3.83	1.19
Mean of STAI-Y1 differences (pre–post, all sessions)	VRMB	6.59	2.71
	VR	5.11	3.26

Table 2 Psychometric questionnaires: pre-treatment and post-treatment scores

Variables	Group			F	p
	VRMB Mean (SD)	VRM	WL		
BAI Pre	26.65 (20.3)	29.4 (11.059)	27.50 (13.204)	0.012	.988
Post	14.50 (10.733)	19.25 (9.7)	19.75 (6.946)		
p	.05	.05	.11		
HAM-A Pre	25.00 (8.679)	19.50 (3.697)	25.00 (7.439)	0.838	.464
Post	15.00 (4.802)	18.75 (9.743)	16.25 (6.702)		
p	.11	.42	.11		
STAI-Y2 Pre	54.15 (2.630)	50.65 (4.573)	59.50 (9.434)	0.471	.539
Post	45.50 (8.396)	46.25 (9.912)	58.00 (5.831)		
p	.05	.11	.54		

Table 3 Demographic details of the sample

Variables	Group			p
	VRMB Mean (SD)	VRM	WL	
Age	45.25 (14.24)	48.5 (12.662)	49.25 (9.845)	.702
Years of education	13.25 (2.1)	12.75 (4.787)	11.25 (4.594)	.455

480 experience and anchor the contents of the VR sessions at
 481 home. When interviewed about the usefulness of mobile
 482 phones, most of the patients (91%) answered that they were
 483 very satisfied because they helped them consolidate the
 484 relaxation training in the absence of the therapist. More-
 485 over, portable devices are useful instruments that can be
 486 used whenever the patient needs them, not only at home,
 487 but also in every real-life situations in which he/she needs
 488 help to relax. This could solve the problem of the lack of
 489 availability of a VR system in the patient’s real-life
 490 context.

491 The study also suggested a possible added value offered
 492 by the use of biofeedback: only in the VRMB group, we
 493 found a significant reduction in two different anxiety scores
 494 (BAI and STAI) after the treatment. As regards the
 495 patients’ physiological responses, we found a tendency
 496 indicating a decrease in HR and GSR between the pre- and
 497 post-session measurements in the VRMB group, higher
 498 than in the VRM group.

499 In conclusion, this study showed that (1) VR can be used
 500 also in the treatment of GAD; (2) in a VR treatment,
 501 patients could take advantage of a mobile device that was
 502 not only well tolerated but also appreciated by the patients.
 503 Despite the need for further analysis, the study also sug-
 504 gested that, with these patients, the effectiveness of an
 505 immersive virtual relaxing environment may be improved
 506 by using physiological data to modify specific features of
 507 the virtual environment in real time.

Acknowledgments The present work was supported by the European Union IST Programme (Project “INTREPID—A Virtual Reality Intelligent Multi-sensor Wearable System for Phobias’ Treatment”—IST-2002-507464). The virtual environments used in the study were developed by the ESIEA INTREPID team (J.L. Dautin, J. Ardouin, F. Crison and M. Le Renard—<http://www.esiea.fr>) using 3DVIA Virtools 4.1.

References

516 1. Sassaroli S, Lorenzini R, Ruggiero GM (2006) Psicoterapia
 517 Cognitiva dell’Ansia—Rimuginio, controllo ed evitamento.
 518 Raffaello Cortina Editore, Milano
 519 2. Michael T, Zetsche U, Margraf J (2007) Epidemiology of anxiety
 520 disorders. *Psychiatry* 6(4):136–142
 521 3. Pull CB (2008) Recent trends in the study of specific phobias.
 522 *Curr Opin Psychiatr* 21(1):43–50
 523 4. Asukai N, Saito A, Tsuruta N, Kishimoto J, Nishikawa T (2010)
 524 Efficacy of exposure therapy for Japanese patients with post-
 525 traumatic stress disorder due to mixed traumatic events: a ran-
 526 domized controlled study. *J Trauma Stress* 23(6):744–750. doi:
 527 [10.1002/jts.20589](https://doi.org/10.1002/jts.20589)
 528 5. Barlow JH, Ellard DR, Hainsworth JM, Jones FR, Fisher A (2005)
 529 A review of self-management interventions for panic disorders,
 530 phobias and obsessive-compulsive disorders. *Acta Psychiatr Scand*
 531 111(4):272–285. doi:[10.1111/j.1600-0447.2005.00499.x](https://doi.org/10.1111/j.1600-0447.2005.00499.x)
 532 6. Craske M, Barlow D (2007) Panic disorder and agoraphobia. In:
 533 Barlow DH (ed) *Clinical handbook of psychological disorders: a*
 534 *step-by-step treatment manual*, 4th edn. Guilford, New York,
 535 pp 1–64
 536 7. Deacon BJ, Abramowitz JS (2004) Cognitive and behavioral
 537 treatments for anxiety disorders: a review of meta-analytic find-
 538 ings. *J Clin Psychol* 60(4):429–441

Author Proof

- 539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
8. Emmelkamp PM (2003) Behavior therapy in adults. In: Handbook of psychotherapy and behavior change. Wiley, New York. pp 393–446
 9. Franklin M, Foa E (2007) Obsessive compulsive disorder. In: Barlow DH (ed) Clinical handbook of psychological disorders: a step-by-step treatment manual, 4th edn. Guilford, New York, pp 164–215
 10. Landon TM, Barlow DH (2004) Cognitive-behavioral treatment for panic disorder: current status. *J Psychiatr Pract* 10(4):211–226
 11. Olatunji BO, Cisler JM, Deacon BJ (2010) Efficacy of cognitive behavioral therapy for anxiety disorders: a review of meta-analytic findings. *Psychiatr Clin North Am* 33(3):557–577. doi:10.1016/j.psc.2010.04.002
 12. Rothbaum BO, Schwartz AC (2002) Exposure therapy for post-traumatic stress disorder. *Am J Psychother* 56(1):59–75
 13. Heimberg R, Dodge C, Hope D, Kennedy C, Zollo L, Becker R (1990) Cognitive behavioural group treatment for social phobia: comparison with a credible placebo control. *Cogn Ther Res* 14:1–23
 14. Wolpe J (1958) Psychotherapy by reciprocal inhibition. Stanford University Press, Stanford
 15. Hazlett-Stevens H, Craske M (2008) Live (in vivo) exposure. In: O'Donohue W, Fisher J (eds) Cognitive behavior therapy—applying empirically supported techniques in your practice, 2nd edn. Wiley, New York
 16. Meichenbaum D (1985) Stress inoculation training. Pergamon Press, Elmsford
 17. Meichenbaum D, Jaremko ME (eds) (1993) Stress reduction and prevention. Plenum Press, New York
 18. Meichenbaum D (2007) Stress inoculation training: a preventative and treatment approach. In: Woolfolk RL, Lehrer PM (eds) Principles and practice of stress management. Guilford, New York, pp 497–518
 19. Villani D, Lucchetta M, Preziosa A, Riva G (2009) The role of interactive media features on the affective response: a virtual reality study. *Int J Human Comput Interact* 1(5):35–55
 20. Villani D, Riva F, Riva G (2007) New technologies for relaxation: the role of presence. *Int J Stress Manag* 14(3):260
 21. Preziosa A, Grassi A, Gaggioli A, Riva G (2009) Therapeutic applications of the mobile phone. *Br J Guid Couns* 37(3):313–325
 22. Repetto C, Gorini A, Algeri D, Vigna C, Gaggioli A, Riva G (2009) The use of biofeedback in clinical virtual reality: the intrepid project. *Stud Health Technol Info* 144:128–132
 23. Repetto C, Gorini A, Vigna C, Algeri D, Pallavicini F, Riva G (2009) The use of biofeedback in clinical virtual reality: the INTREPID project. *J Vis Exp JoVE* (33):2–3
 24. Meichenbaum D (2006) Trauma and suicide. In: Ellis T (ed) Cognition and suicide: theory, research and practice. American Psychological Association, Washington, DC
 25. Steer RA, Rissmiller DJ, Ranieri WF, Beck AT (1993) Structure of the computer-assisted Beck anxiety inventory with psychiatric inpatients. *J Pers Assess* 60(3):532–542
 26. Spielberger CD, Gorsuch RL, Lushene RE (1970) STAI manual for the state-trait anxiety inventory (self-evaluation questionnaire). Consulting Psychologists, Palo Alto
 27. Hamilton M (1959) The assessment of anxiety states by rating. *Br J Med Psychol* 32(1):50–55
 28. Achmon J, Granek M, Golomb M, Hart J (1989) Behavioral treatment of essential hypertension: a comparison between cognitive therapy and biofeedback of heart rate. *Psychosom Med* 51(2):152–164
 29. Benson H, Shapiro D, Tursky B, Schwartz GE (1971) Decreased systolic blood pressure through operant conditioning techniques in patients with essential hypertension. *Science* 173(3998):740
 30. Blanchard EB, Young LD, Haynes MR (1975) A simple feedback system for the treatment of elevated blood pressure. *Behav Ther* 6(2):241–245
 31. Elder ST, Eustis NK (1975) Instrumental blood pressure conditioning in out-patient hypertensives. *Behav Res Ther* 13(2–3):185–188
 32. Siegel S, Castellan NJ (1992) Nonparametric statistics for the behavioral sciences. McGraw-Hill, Milano
 33. Repetto C, Riva G (2011) From virtual reality to interreality in the treatment of anxiety disorders. *Neuropsychiatry* 1(1):31–43
 34. Riva G (2005) Virtual reality in psychotherapy: review. *Cyberpsychol Behav* 8:220–230
- 579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615